Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1826879rdf:typepubmed:Citationlld:pubmed
pubmed-article:1826879lifeskim:mentionsumls-concept:C0020792lld:lifeskim
pubmed-article:1826879lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:1826879lifeskim:mentionsumls-concept:C0025914lld:lifeskim
pubmed-article:1826879lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:1826879lifeskim:mentionsumls-concept:C0022646lld:lifeskim
pubmed-article:1826879lifeskim:mentionsumls-concept:C0023810lld:lifeskim
pubmed-article:1826879lifeskim:mentionsumls-concept:C0063710lld:lifeskim
pubmed-article:1826879lifeskim:mentionsumls-concept:C0475264lld:lifeskim
pubmed-article:1826879lifeskim:mentionsumls-concept:C1709059lld:lifeskim
pubmed-article:1826879pubmed:issue5lld:pubmed
pubmed-article:1826879pubmed:dateCreated1991-5-24lld:pubmed
pubmed-article:1826879pubmed:abstractTextThe cytokine interleukin-1 (IL-1) has a variety of effects in the kidney involving induction of nephritis and renal injury. In addition, recent reports suggest that IL-1 regulates natriuresis and renin secretion in the kidney. To examine the potential sites of action of IL-1 in the kidney, we used iodine-125-labeled recombinant human interleukin-1 alpha ([125I]IL-1 alpha) to identify and characterize IL-1 receptors in crude membrane preparations of mouse (C57BL/6) kidney. The binding of [125I] IL-1 alpha was linear over a broad range of membrane protein concentrations, saturable, reversible, and of high affinity, with an equilibrium dissociation constant (Kd) of 66 +/- 10 pM and a maximum number of binding sites of 1.04 +/- 0.24 fmol/mg protein. In competition studies, recombinant human IL-1 alpha, recombinant human IL-1 beta, and a weak IL-1 beta analog (IL-1 beta+) inhibited [125I]IL-1 alpha binding to mouse kidney in parallel with their relative bioactivities in the T-cell comitogenesis assay, with inhibitory binding affinity constant (Ki) values of 28 +/- 19, 53 +/- 23, and 5560 +/- 2098 pM, respectively; rat/human CRF and human tumor necrosis factor had no effect on [125I]IL-1 alpha binding. In autoradiographic studies, IL-1 receptors were heterogeneously distributed in the kidney, with significantly higher densities present in the medulla than in the cortex. To study the effects of endogenous IL-1 in modulating [125I]IL-1 alpha-binding sites in kidney, we injected 30 micrograms of the bacterial endotoxin lipopolysaccharide (LPS) to mice ip. Autoradiographic studies demonstrated substantial decreases in [125I]IL-1 alpha binding in both the kidney cortex (control, 34.7 +/- 6.2 fmol/mg tissue equivalent; LPS, 11.3 +/- 0.3; P less than 0.05) and medulla (52.7 +/- 8.1 vs. 26.0 +/- 1.0; P less than 0.05) 24 h after injection of LPS. Saturation studies in whole kidney homogenates demonstrated that the LPS-induced decrease in [125I]IL-1 alpha binding was primarily due to a down-regulation of IL-1 receptors (i.e. decrease in the maximum number of binding sites). The identification of IL-1 receptors in kidney with characteristics similar to those of IL-1 receptors in the brain-endocrine-immune axis provides further support for a physiological role for IL-1 in regulating renal function.lld:pubmed
pubmed-article:1826879pubmed:languageenglld:pubmed
pubmed-article:1826879pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1826879pubmed:citationSubsetAIMlld:pubmed
pubmed-article:1826879pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1826879pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1826879pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1826879pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1826879pubmed:statusMEDLINElld:pubmed
pubmed-article:1826879pubmed:monthMaylld:pubmed
pubmed-article:1826879pubmed:issn0013-7227lld:pubmed
pubmed-article:1826879pubmed:authorpubmed-author:MitchellW MWMlld:pubmed
pubmed-article:1826879pubmed:authorpubmed-author:TakaoTTlld:pubmed
pubmed-article:1826879pubmed:authorpubmed-author:de SouzaE BEBlld:pubmed
pubmed-article:1826879pubmed:issnTypePrintlld:pubmed
pubmed-article:1826879pubmed:volume128lld:pubmed
pubmed-article:1826879pubmed:ownerNLMlld:pubmed
pubmed-article:1826879pubmed:authorsCompleteYlld:pubmed
pubmed-article:1826879pubmed:pagination2618-24lld:pubmed
pubmed-article:1826879pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:1826879pubmed:meshHeadingpubmed-meshheading:1826879-...lld:pubmed
pubmed-article:1826879pubmed:meshHeadingpubmed-meshheading:1826879-...lld:pubmed
pubmed-article:1826879pubmed:meshHeadingpubmed-meshheading:1826879-...lld:pubmed
pubmed-article:1826879pubmed:meshHeadingpubmed-meshheading:1826879-...lld:pubmed
pubmed-article:1826879pubmed:meshHeadingpubmed-meshheading:1826879-...lld:pubmed
pubmed-article:1826879pubmed:meshHeadingpubmed-meshheading:1826879-...lld:pubmed
pubmed-article:1826879pubmed:meshHeadingpubmed-meshheading:1826879-...lld:pubmed
pubmed-article:1826879pubmed:meshHeadingpubmed-meshheading:1826879-...lld:pubmed
pubmed-article:1826879pubmed:meshHeadingpubmed-meshheading:1826879-...lld:pubmed
pubmed-article:1826879pubmed:meshHeadingpubmed-meshheading:1826879-...lld:pubmed
pubmed-article:1826879pubmed:meshHeadingpubmed-meshheading:1826879-...lld:pubmed
pubmed-article:1826879pubmed:meshHeadingpubmed-meshheading:1826879-...lld:pubmed
pubmed-article:1826879pubmed:year1991lld:pubmed
pubmed-article:1826879pubmed:articleTitleInterleukin-1 receptors in mouse kidney: identification, localization, and modulation by lipopolysaccharide treatment.lld:pubmed
pubmed-article:1826879pubmed:affiliationNeurobiology Laboratory, National Institute on Drug Abuse, Baltimore, Maryland 21224.lld:pubmed
pubmed-article:1826879pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1826879lld:pubmed